In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 376 to 400 of 434

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Tafasitamab with lenalidomide and R-CHOP for untreated high-intermediate-risk or high-risk diffuse large B-cell lymphoma [ID6568]	Technology appraisal guidance	10 June 2027
Tafasitamab with lenalidomide and rituximab for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments ID6413	Technology appraisal guidance	15 July 2026
Talacotuzumab for untreated acute myeloid leukaemia [ID1262]	Technology appraisal guidance	TBC
Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer [ID4004]	Technology appraisal guidance	3 December 2025
Targeted-release budesonide for treating primary IgA nephropathy (review of TA937) [ID6485]	Technology appraisal guidance	25 February 2026
Tarlatamab for treating small-cell lung cancer that has progressed after platinum-based chemotherapy ID6617	Technology appraisal guidance	TBC
Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women ID1401	Technology appraisal guidance	TBC
Technologies to support self-monitoring of vision change for people with macular disease (provisional title)	Health technology evaluation	TBC
Technologies to support the rapid diagnosis of endometriosis (provisional title)	Health technology evaluation	TBC
Teclistamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more therapies [ID6201]	Technology appraisal guidance	28 July 2027
Telisotuzumab vedotin for treating c-MET overexpressed, EGFR wild-type, non-squamous advanced non-small-cell lung cancer after 1 or more systemic treatments [ID6253]	Technology appraisal guidance	TBC
Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes [ID6259]	Technology appraisal guidance	8 April 2026
Teprotumumab for treating thyroid eye disease [ID6432]	Technology appraisal guidance	TBC
Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps ID6379	Technology appraisal guidance	TBC
Third molars (impacted) - prophylactic removal [ID898]	Technology appraisal guidance	TBC
Tiragolumab with atezolizumab and bevacizumab for untreated unresectable or advanced hepatocellular carcinoma [TSID12238]	Technology appraisal guidance	TBC
Tiragolumab with atezolizumab for treating advanced oesophageal squamous cell cancer after chemoradiotherapy [ID6267]	Technology appraisal guidance	TBC
Tiragolumab with atezolizumab for treating locally advanced unresectable stage 3 non-small-cell lung cancer after at least 2 cycles of platinum-based chemoradiation [ID6250]	Technology appraisal guidance	TBC
Tiragolumab with atezolizumab for untreated PD-L1-positive advanced non-small-cell lung cancer [ID5122]	Technology appraisal guidance	TBC
Tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer ID5113	Technology appraisal guidance	TBC
Tislelizumab with chemotherapy for untreated unresectable or metastatic gastric or gastro-oesophageal junction cancer [ID6157]	Technology appraisal guidance	TBC
Tislelizumab with platinum-based chemotherapy and etoposide for untreated extensive-stage small-cell lung cancer [ID6158]	Technology appraisal guidance	TBC
Tisotumab vedotin for treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatment [ID3753]	Technology appraisal guidance	25 June 2026
Tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations [ID3767]	Highly specialised technology	TBC
Tolebrutinib for treating non-relapsing secondary progressive multiple sclerosis ID6351	Technology appraisal guidance	TBC

Results per page

10
25
50
All